Suppr超能文献

阿司匹林剂量对糖尿病和非糖尿病患者血小板功能的影响:来自阿司匹林诱导血小板效应(ASPECT)研究的分析。

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.

作者信息

DiChiara Joseph, Bliden Kevin P, Tantry Udaya S, Hamed Miruais S, Antonino Mark J, Suarez Thomas A, Bailon Oscar, Singla Anand, Gurbel Paul A

机构信息

Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 W. Belvedere Ave., Baltimore, MD 21215, USA.

出版信息

Diabetes. 2007 Dec;56(12):3014-9. doi: 10.2337/db07-0707. Epub 2007 Sep 11.

Abstract

OBJECTIVE

Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients.

RESEARCH DESIGN AND METHODS

We examined the effect of aspirin (81, 162, and 325 mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpatients (30 diabetic patients and 90 nondiabetic patients) with coronary artery disease (CAD) using light transmittance aggregometry (LTA), VerifyNow, platelet function analyzer (PFA)-100, and levels of urinary 11-dehydro-thromboxane B(2) (11-dh-TxB(2)).

RESULTS

In the total group, a low prevalence (0-2%) of aspirin resistance was observed with all aspirin doses as determined by arachidonic acid-induced LTA. Aspirin resistance was higher at the 81-mg dose in diabetic versus nondiabetic patients using collagen-induced LTA (27 vs. 4%, P = 0.001), VerifyNow (13 vs. 3%, P = 0.05), and urinary 11-dh-TxB(2) (37 vs. 17%, P = 0.03). Diabetic patients treated with 81 mg exhibited higher platelet function measured by VerifyNow, collagen- and ADP-induced LTA, and 11-dh-TxB(2) levels (P <or= 0.02 for all comparisons). Higher aspirin doses significantly inhibited platelet function and decreased aspirin resistance in diabetic patients (P < 0.05).

CONCLUSIONS

Diabetic patients with CAD treated with 81 mg aspirin exhibit a higher prevalence of aspirin resistance and have significantly higher ADP- and collagen-induced platelet aggregation, 11-dh-TxB(2) levels, and aspirin reaction units measured by VerifyNow than nondiabetic patients. Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups. These findings indicate that diabetic patients exhibit a global high platelet reactivity phenotype that may be partially overcome by higher aspirin doses.

摘要

目的

糖尿病患者血小板对阿司匹林抵抗的发生率可能高于非糖尿病患者。我们的目标是分析糖尿病和非糖尿病患者血小板对不同剂量阿司匹林的反应性。

研究设计与方法

我们使用透光率聚集法(LTA)、VerifyNow、血小板功能分析仪(PFA)-100以及尿11-脱氢血栓素B2(11-dh-TxB2)水平,检测了阿司匹林(81、162和325mg/天,各服用4周)对120例稳定的门诊冠心病(CAD)患者(30例糖尿病患者和90例非糖尿病患者)血小板对阿司匹林反应性的影响。

结果

在总人群中,通过花生四烯酸诱导的LTA测定,所有阿司匹林剂量下阿司匹林抵抗的发生率均较低(0-2%)。使用胶原诱导的LTA(27%对4%,P=0.001)、VerifyNow(13%对3%,P=0.05)和尿11-dh-TxB2(37%对17%,P=0.03),糖尿病患者在81mg剂量时的阿司匹林抵抗高于非糖尿病患者。服用81mg的糖尿病患者通过VerifyNow、胶原和ADP诱导的LTA以及11-dh-TxB2水平测量的血小板功能更高(所有比较P≤0.02)。更高剂量的阿司匹林显著抑制了糖尿病患者的血小板功能并降低了阿司匹林抵抗(P<0.05)。

结论

与非糖尿病患者相比,服用81mg阿司匹林治疗的CAD糖尿病患者阿司匹林抵抗的发生率更高,且通过VerifyNow测量的ADP和胶原诱导的血小板聚集、11-dh-TxB2水平以及阿司匹林反应单位显著更高。增加阿司匹林剂量导致两组之间的抵抗率和血小板功能水平相似。这些发现表明,糖尿病患者表现出整体高血小板反应性表型,较高剂量的阿司匹林可能会部分克服这一表型。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验